Change in substantial holding
04 July 2018 Enclosed is a notice of a change in substantial...
Read More
CLINUVEL COMPLETES SCENESSE® FDA FILING
25 June 2018 EXECUTIVE SUMMARY First NDA for SCENESSE® (afamelanotide 16mg) in...
Read More
Trading Halt
22 June 2018 Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV)...
Read More
NICE MAINTAINS ITS POSITION NOT TO RECOMMEND SCENESSE® FOR REIMBURSEMENT
23 May 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
Change in substantial holding
17 May 2018 Enclosed is a notice of a change in substantial...
Read More
Change in substantial holding
Change in substantial holding Download attachments: 20180516Changeinsubstantialholding.pdf
Read More
CLINUVEL REGULATORY UPDATE
14 May 2018 CLINUVEL PHARMACEUTICALS LTD today provided an update on its global...
Read More
Change in substantial holding
01 May 2018 Enclosed is a notice of a change of interests...
Read More
CLINUVEL TO TAKE 100% OWNERSHIP OF VALLAURIX
01 May 2018 CLINUVEL PHARMACEUTICALS LTD today announced that it has entered into...
Read More
Appendix 4C
30 April 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION:...
Read More
CLINUVEL Newsletter - March 2018
26 March 2018 The erythropoietic protoporphyria (EPP) Expert Meeting in Vienna on...
Read More
CLINUVEL HOLDS EUROPEAN ERYTHROPOIETIC PROTOPORPHYRIA (EPP) EXPERT MEETING
19 March 2018 CLINUVEL PHARMACEUTICALS LTD today announced the results of the third...
Read More
CLINUVEL sustains profitability first-half of year
28 February 2018 CLINUVEL PHARMACEUTICALS LTD today announced financial results for the half...
Read More
CLINUVEL unveils new global positioning
20 February 2018 CLINUVEL PHARMACEUTICALS LTD today released its new global Company positioning...
Read More